Background and aims: Steroid therapy is the first-line treatment for autoimmune pancreatitis but relapses are frequent. The aims were to assess the efficacy and the safety of immunomodulator treatments for relapsing autoimmune pancreatitis and rituximab in particular and to identify relapsing risk factors.
Methods: Patients followed for autoimmune pancreatitis from 2000 to 2016 were included. Data were retrospectively analysed regarding autoimmune pancreatitis treatment.
Results: In total, 162 patients with autoimmune pancreatitis type 1 (n = 92) and type 2 (n = 70) were included (median follow-up: 3 years (0.5-14). Relapse occurred in 46.5% of patients with autoimmune pancreatitis type 1 (vs 19.3% in autoimmune pancreatitis 2; p < 0.001). Risk factors of relapse were cholangitis, initial use of steroids, other organ involvement and chronic pancreatitis in autoimmune pancreatitis type 1 and initial use of steroids, tobacco consumption and chronic pancreatitis for autoimmune pancreatitis type 2. Overall, 21 patients were treated with immunomodulators (azathioprine, n = 19, or methotrexate, n = 2) for relapses. The efficiency rate was 67%. A total of 17 patients were treated with rituximab, with two perfusions at 15 days apart. The efficacy was 94% (16/17), significantly better than immunomodulator drugs (p = 0.03), with a median follow-up of 20 months (11-44). Only two patients needed two supplementary perfusions.
Conclusion: In relapsing autoimmune pancreatitis, rituximab is more efficient than immunomodulator drugs and shows better tolerance.
Keywords: Autoimmune pancreatitis; IgG4 related disease; azathioprine; cholangitis; rituximab.
© Author(s) 2019.
Treatment of Relapsing Autoimmune Pancreatitis With Immunomodulators and Rituximab: The Mayo Clinic ExperiencePA Hart et al. Gut 62 (11), 1607-15. PMID 22936672.In type 1 AIP relapses are common. Relapse-free survival is similar in those treated with steroids plus IM compared to those treated with steroids alone. Nearly half the …
[Rituximab Therapy for Relapsing IgG4-autoimmune Pancreatitis and Cholangitis - A Case Report]J Mueller et al. Z Gastroenterol 53 (1), 40-2. PMID 25594706. - Case ReportsWe report a patient with autoimmune pancreatitis and cholangitis. During a period of 3 years and despite therapy with steroids and immunmodulatory drugs such as azathiopr …
Diagnosis and Management of Autoimmune PancreatitisPA Hart et al. Curr Treat Options Gastroenterol 15 (4), 538-547. PMID 28842855. - ReviewAlthough autoimmune pancreatitis is a relatively uncommon pancreatic disorder, it is an important consideration in the differential diagnosis of jaundice and pancreatic m …
Relapse Rate and Predictors of Relapse in a Large Single Center Cohort of Type 1 Autoimmune Pancreatitis: Long-Term Follow-Up Results After Steroid Therapy With Short-Duration Maintenance TreatmentHW Lee et al. J Gastroenterol 53 (8), 967-977. PMID 29362937.Type 1 AIP has common relapses, and patients with OOI, especially OOI of the proximal bile duct, appear to be at increased risk for relapse. Long-term sequelae, including …
Autoimmune PancreatitisS Majumder et al. Dig Dis Sci 62 (7), 1762-1769. PMID 28365915. - ReviewAutoimmune pancreatitis (AIP) is a chronic fibroinflammatory disease of the pancreas that belongs to the spectrum of immunoglobulin G-subclass4-related diseases (IgG4-RD) …
Cited by 1 PubMed Central articles
Steroid Therapy and Steroid Response in Autoimmune PancreatitisH Matsubayashi et al. Int J Mol Sci 21 (1). PMID 31905944. - ReviewAutoimmune pancreatitis (AIP), a unique subtype of pancreatitis, is often accompanied by systemic inflammatory disorders. AIP is classified into two distinct subtypes on …